Primary Bioscience

Executive Summary

Primary Bioscience is developing a groundbreaking single-molecule protein sequencing platform designed to enable comprehensive, unbiased multi-biomarker screening. By sequencing every protein in a sample, the technology captures difficult-to-detect variations such as single-residue substitutions, splice variants, and post-translational truncations, offering unprecedented resolution for diagnostics and digital health applications. Founded in 2018 and headquartered in San Diego, the company aims to address critical gaps in proteomics, where current methods lack the sensitivity and breadth needed for early disease detection and personalized medicine. While still in the development stage, Primary Bioscience's approach could revolutionize diagnostic testing by providing a single, holistic snapshot of the proteome, potentially outperforming existing antibody-based assays and mass spectrometry in scalability and throughput. The company operates in a highly competitive and innovative space, with significant unmet need for high-throughput protein analysis. Given its early stage, Primary Bioscience has not yet disclosed funding rounds or clinical partnerships, but its novel technology positions it as a potential disruptor. Execution risks remain high, including technical validation, manufacturing scale-up, and regulatory pathway. However, if successful, the platform could unlock new biomarker discovery and diagnostic capabilities, addressing markets from oncology to neurodegenerative diseases. Near-term focus will likely be on securing Series A financing and generating proof-of-concept data to attract strategic partners and advance toward commercialization.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing70% success
• Q4 2026First Proof-of-Concept Data Release55% success
• Q1 2027Strategic Partnership with Diagnostics Firm45% success